Data from patient-supported outcomes can be captured through qualitative research and can then be used in quantitative research designs.
The new Global Medical Information and Education Office (GMIE) is leveraging technology and expertise to deliver practical, flexible, and innovative programs.
Real-world evidence can help expand our understanding of the effectiveness of various interventions for people with end stage kidney disease.
Learn how we took the lead in developing strategies to protect patients, families, caregivers, and clinical staff from COVID-19.
During the COVID-19 pandemic, we deployed our Disaster Relief Team and created a pool of dialysis equipment to meet the increased demand of acute kidney injury patients.
As several different COVID-19 vaccines are authorized for emergency use and/or approved around the world, the race to contain the pandemic has been given a new weapon.
While current COVID-19 vaccines are very effective, manufacturers are developing strategies to ensure that new vaccines can keep pace with the rapid rate of mutation.
While global COVID-19 data confirms that dialysis patients experienced a high rate of hospitalization and death, there has been insufficient research into many issues surrounding individuals with end stage kidney disease.
The Centers for Medicare and Medicaid Services (CMS) established the end stage renal disease Prospective Payment System (PPS) to facilitate beneficiary access to renal dialysis equipment.
We are driving innovation and transformation in kidney care with research into regenerative medicine, organ transplant, and organ recovery.
Our Global Medical Office has started a program to understand regional factors affecting performance in improving care for people with end stage kidney disease.
We're taking a multifaceted approach to advancing transplantation including technologies to expand the pool of kidneys available for transplant.
Patients who are active partners in their care report better physiological and psychological outcomes compared to those in more traditional dialysis care settings.
Precision medicine requires properly recognizing the right patient, having the right drugs, and knowing the right time to apply them.
By creating genomic and phenotype data sets for more than 100,000 patients, researchers can begin to unlock the complexities of CKD.
The risk of cardiovascular disease increases with the progression of CKD, so cardiovascular health is an essential component of CKD management.
We developed an ultrafiltration (UF) control algorithm to attain favorable relative blood volume (RBV) ranges by comparing the RBV profile to the target curve and making UF adjustments.
The ability to take healthcare innovations and learnings from one locale to another has helped us make an impact in communities worldwide.
Cardiac disease prevention and management is one of the most important clinical targets in patients receiving maintenance dialysis.
Starting dialysis in a planned way with a permanent access results in better early dialysis outcomes, improved quality of life, and lower healthcare costs.
Our connected health platforms empower patients and clinical staff through a digital ecosystem that connects patients with healthcare professionals, medical devices, and customer service.
We are devoted to providing precise and personalized care while improving vascular access for people on hemodialysis.
The digital health era now offers tools for transforming clinical research through improved efficiencies of highly complex trials.
Our Global Medical Office has created an interdisciplinary critical care team to help develop new critical care delivery improvements.